Endocervical prostaglandin E2 gel for preinduction cervical softening

M. Thiery, J. M. Decoster, W. Parewijck, M. L. Noah, R. Derom, H. Van Kets, P. Defoort, W. Aertsens, G. Debruyne, K. De Geest, F. Vandekerckhove

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


A single, endocervical application of a new commercial preparation of prostaglandin E2 (PGE2) gel, 0.5 mg of PGE2 in 2.5 ml (3g), was evaluated for preinduction cervical softening. Safety and efficacy were assessed in a comparison with a 2.0 mg PGE2 vaginal tablet and placebo in normal nulliparous women at term, with low Bishop scores. Treatment was administered in randomized, double blind fashion. Overall success, defined as a progression in Bishop score of at least 3 points within 12 hours, was achieved in 22/40 (55 %) of the gel group, 15/41 (37 %) in the tablet treated women, and 8/40 (20 %) in those receiving placebo. Od interest was the observation that of women with very unfavorable induction features (Bishop score 0-2), the cervical gel treatment resulted in a 6/8 (75 %) success rate compared with 2/13 (15 %) success for the vaginal tablet and 0/7 (0 %) for placebo. In as much as a very low incidence of side effects accompanied this treatment scheme, expanded multi-center testing is recommended.

Original languageEnglish (US)
Pages (from-to)429-439
Number of pages11
Issue number3
StatePublished - Mar 1984
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Endocervical prostaglandin E2 gel for preinduction cervical softening'. Together they form a unique fingerprint.

Cite this